Irinotecan in patients with relapsed or cisplatin-refractory germ cell cancer: A phase II study of the German Testicular Cancer Study Group

British Journal of Cancer

Volumn 87, Issue 7, 2002, Pages 729-732

  Kollmannsberger, C ^a   Rick, O ^b   Klaproth, H ^c   Kubin, T ^d   Sayer, H G ^e   Hentrich, M ^f   Welslau, M ^g   Mayer, F ^a   Kuczyk, M ^h   Spott, C ^a   Kanz, L ^a   Bokemeyer, Carsten ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b Department of Haematology/Oncology ^*  (Germany)

^c UNIVERSITY OF GÖTTINGEN   (Germany)

^d STÄDTISCHES KLINIKUM KARLSRUHE   (Germany)

^e FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^f Krankenhaus Harlaching   (Germany)

^g Onkologische Praxis Klausmann Welslau   (Germany)

^h HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Cisplatin refractory; Germ cell cancer (GCT); Irinotecan; Palliative chemotherapy; Relapse

Indexed keywords

ANTIEMETIC AGENT; CISPLATIN; DEXAMETHASONE; IRINOTECAN; SEROTONIN ANTAGONIST;

ADULT; ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RECURRENCE; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG ACTIVITY; DRUG INDUCED DISEASE; FEVER; GERM CELL TUMOR; HUMAN; LEUKOPENIA; MALE; METASTASIS; NAUSEA AND VOMITING; PHASE 2 CLINICAL TRIAL; POLYNEUROPATHY; PRIORITY JOURNAL; PROGNOSIS; SALVAGE THERAPY; TESTIS CANCER; THROMBOCYTOPENIA; XENOGRAFT;

ADULT; CAMPTOTHECIN; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; GERMANY; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, GERM CELL AND EMBRYONAL; TESTICULAR NEOPLASMS;

EID: 18644382336     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.66000524     Document Type: Article

References (32)

1. Beyer J, Kramar A, Mandanas R, Linkesch W, Greinix A, Droz JP, Pico JL, Diehl A, Bokemeyer C, Schmoll HJ, Nichols CR, Einhorn LH, Siegert W (1996) High-dose chemotherapy as salvage treatment in germ cell tumours: A multivariate analysis of prognostic variables. J Clin Oncol 14: 2638-2645
2. Bokemeyer C, Beyer J, Metzner B, Rüther U, Harstrick A, Weißbach L, Köhrmann U, Verbeek W, Schmoll HJ (1996) Phase II study of paclitaxel in patients with relapsed or cisplatin-refractory testicular cancer. Ann Oncol 7: 31-34
3. Bokemeyer C, Droz JP, Hanauske A, Schröder M, Queißer W, Schmoll HJ (1993) Treatment of relapsed nonseminomatous germ cell tumours with vinorelbine: A trial of the phase I/II study group of the Association of Medical Oncology of the German Cancer Society. Onkologie 16: 29-31
4. Bokemeyer C, Gerl A, Schöffski P, Harstrick A, Niederle N, Beyer J, Casper J, Schmoll HJ, Kanz L (1999) Gemcitabine in patients with relapsed or cisplatin-refractory testicular cancer. J Clin Oncol 17: 512-516
5. Bosl GJ, Motzer RJ (1997) Medical progress: Testicular germ-cell cancer. N Engl J Med 337: 242-253
6. Bregni M, Marzola M, DiNicola M, Bonazzi C, Siena S, Cantu MG, Matteucci P, Lissoni A, Magni M, Miceli D, Devizzi L, Vecchione F, Gianni AM (1998) Full-dose conventional chemotherapy is feasible and effective after tandem high-dose chemotherapy supported by mobilized blood autografting. Proc Am Soc Clin Oncol 17: 89a (abstract 342)
7. Constenla M, Lorenzo I, Garcia Arroyo FR, Rey C, Carrete N (1998) Taxane treatment of relapsed breast cancer after high-dose chemotherapy & autologous PBPC-transplantation. Bone Marrow Transplant 21:(suppl. 1): 57
8. Creemers GJ, Lund B, Verweij J (1994) Topoisomerase I inhibitors: topotecan and irenotecan. Cancer Treat Rev 20: 73-96
9. Cunningham D, Pyrhonen S, James RD, Punt CJ, Hickish TF, Heikkila R, Johannesen TB, Starkhammar H, Topham CA, Awad L, Jacques C, Herait P (1998) Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 352: 1413-1418
10. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L, Rougier P (2000) Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355: 1041-1047
11. Drasga RE, Williams S, Einhorn LH, Birch R (1987) Phase II evaluation of iproplatin in refractory germ cell tumours: A Southeastern Cancer Study Group trial. Cancer Treat Rep 71: 863-864
12. Einhorn LH (1990) Treatment of testicular cancer: A new and improved model. J Clin Oncol 8: 1777-1781
13. Einhom LH, Stender MJ, Williams SD (1999) Phase II trial of gemcitabine in refractory germ cell tumours. J Clin Oncol 17: 509-511
14. Gehan E (1961) The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent. J Chron Dis 13: 346-353
15. Kollmannsberger C, Gerl A, Schleucher N, Beyer J, Rick O, Casper J, Sosada M, Kanz L, Bokemeyer C (2000) Phase II study of bendamustine in patients with relapsed or cisplatin-refractory germ cell cancer. Anticancer Drugs 11: 535-539
16. Kollmannsberger C, Rick O, Beyer J, Derigs H-G, Mayer F, Schleucher N, Schoeffski P, Sosada M, Spott C, Kanz L, Bokemeyer C (2001) Oxaliplatin in patients (pts) with cisplatin-refractory germ cell cancer (GCT). Proc Am Soc Clin Oncol 20: 193a (abstract 770)
17. Miki T, Sawada M, Nonomura N, Kojima Y, Okuyama A, Maeda O, Saiki S, Kotake T (1997) Antitumour effect of CPT-11, a camptothecin derivative, on human testicular tumour xenografts in nude mice. Eur Urol 31: 92-96
18. Miller AB, Hoodgstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47: 207-211
19. Miller JC, Einhorn LH (1990) Phase II study of daily oral etoposide in refractory germ cell tumours. Semin Oncol 17: 36-39
20. Motzer RJ, Bajorin D, Schwartz LH, Hutter HS, Bosl GJ, Scher H, Lyn P, Fischer P (1994) Phase II trial of paclitaxel shows antitumour activity in patients with previously treated germ cell tumours. J Clin Oncol 12: 2277-2283
21. Motzer RJ, Sheinfeld J, Mazumdar M, Bains M, Mariani T, Bacik J, Bajorin D, Bosl G (2000) Paclitaxel, ifosfamide, and cisplatin second-line therapy for patients with relapsed testicular germ cell cancer. J Clin Oncol 18: 2413-2418
22. Murphy B, Motzer RJ, Bosl GJ (1992) Phase II study of iproplatin (CHIP) in patients with cisplatin-refractory germ cell tumours; the need for alternative strategies in the investigation of new agents in GCT. Invest New Drugs 10: 327-330
23. Nichols CR, Roth BJ, Loehrer PJ, Williams SD, Einhorn LH (1994) Salvage chemotherapy for recurrent germ cell cancer. Semin Oncol 5:(suppl 12): 102-108
24. Nichols CR, Tricot G, Williams SD, van Besien K, Loehrer PJ, Roth BJ, Akard L, Hoffman R, Goulet R, Wolff SN, Giannone L, Greer J, Einhorn LH, Jansen J (1989) Dose-intensive chemotherapy in refractory germ cell cancer - a phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation. J Clin Oncol 7: 932-939
25. Nomoto T, Miki T, Nakao M, Mizutani Y, Nakagawa S, Nakamura T, Nonomura N, Okuyama A, Saiki S, Kotake T (2000) Salvage chemotherapy with CPT-11 and cisplatin for cisplatin-refractory germ cell cancer. Proc Am Soc Clin Oncol 19: 351a (abstract 1383)
26. Porcu P, Bhatia S, Einhorn LH (2000) Results of treatment after relapse from high-dose chemotherapy in germ cell tumours. J Clin Oncol 18: 1181-1186
27. Puc HS, Bajorin D, Bosl GJ, Amsterdam A, Motzer RJ (1995) Phase II trial of topotecan in patients with cisplatin-refractory germ cell tumours. Invest New Drugs 13: 163-165
28. Rocha-Lima CM, Sherman CA, Brescia FJ, Brunson CY, Green MR (2001) Irinotecan/gemcitabine combination chemotherapy in pancreatic cancer. Oncology (Huntingt) 15: 46-51
29. Rosen LS (1998) Irinotecan in lymphoma, leukemia, and breast, pancreatic, ovarian, and small-cell lung cancers. Oncology (Huntingt) 12: 103-109
30. Sola C, Lluch A, Garcia-Conde J, Ojeda B, Horendo J, Benavides M, Solano C, Garcia-Salazar T, Alonso S, Cortes-Funes H, Lopez JJ (1999) Phase II study of weekly paclitaxel in recurrent breast cancer after high-dose chemotherapy. Proc Am Soc Clin Oncol 17: 174a (abstract 245)
31. Takeda K, Negoro S, Takifuji N, Nitta T, Yoshimura N, Terakawa K, Fukuoka M (2001) Dose escalation study of irinotecan combined with carboplatin for advanced non-small-cell lung cancer. Cancer Chemother Pharmacol 48: 104-108
32. Ueoka H, Tanimoto M, Kiura K, Tabata M, Takigawa N, Segawa Y, Takata I, Eguchi K, Okimoto N, Harita S, Kamei H, Shibayama T, Watanabe Y, Hiraki S, Harada M (2001) Fractionated administration of irinotecan and cisplatin for treatment of non-small-cell lung cancer: a phase II study of Okayama Lung Cancer Study Group. Br J Cancer 85: 9-13